Skip Navigation

Cardiovascular Research 2006 69(3):595-603; doi:10.1016/j.cardiores.2005.11.026
This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrowRequest Permissions
Google Scholar
Right arrow Articles by Sluijter, J. P.G.
Right arrow Articles by Pasterkamp, G.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Sluijter, J. P.G.
Right arrow Articles by Pasterkamp, G.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

Copyright © 2005, European Society of Cardiology

Vascular remodeling and protease inhibition–bench to bedside

Joost P.G. Sluijtera,b, Dominique P.V. de Kleijna,b and Gerard Pasterkampa,*

aExperimental Cardiology Laboratory, Department of Cardiology, University Medical Center Utrecht, Heidelberglaan 100, Room G02-523, 3584 CX Utrecht, The Netherlands
bInteruniversity Cardiology Institute of the Netherlands (ICIN), Utrecht, The Netherlands

* Corresponding author. Tel.: +31 30 250 7155; fax: +31 30 252 2693. Email address: g.pasterkamp{at}hli.azu.nl

Physiological and pathological tissue remodeling needs an orderly degradation of the extracellular matrix. Matrix metalloproteinases (MMPs) are proteases capable of degrading different extracellular matrix components, including collagen and elastin. MMP expression is strongly enhanced in vascular pathologies such as stenosis following balloon dilation, in-stent restenosis, sustained flow changes, aneurysm formation, and atherosclerosis. Experimental studies have revealed that some biological actions of MMPs aggravate a pathological condition, whereas others may be beneficial for the patient suffering from atherosclerotic disease. Therefore, a better understanding of the biological consequence and regulation of MMP activity is critical for the design and potential application of specific MMP inhibitors in vascular disease.

In this review, we will give an overview of preclinical experimental studies using MMP inhibitors with the objective to influence vascular occlusive diseases, and we will also highlight new targets that influence MMP expression and activity and that possess potential for therapeutic interventions.

KEYWORDS Vascular remodeling; Matrix metalloproteinases (MMP); MMP inhibition; Atherosclerosis

Time for primary review 27 days


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
 Arterioscler. Thromb. Vasc. Bio.Home page
Y. Hou, K. Okada, C. Okamoto, S. Ueshima, and O. Matsuo
Alpha2-Antiplasmin Is a Critical Regulator of Angiotensin II-Mediated Vascular Remodeling
Arterioscler. Thromb. Vasc. Biol., July 1, 2008; 28(7): 1257 - 1262.
[Abstract] [Full Text] [PDF]

Home page
 Cardiovasc ResHome page
A. C. Newby, M. Pauschinger, and F. G. Spinale
From tadpole tails to transgenic mice: Metalloproteinases have brought about a metamorphosis in our understanding of cardiovascular disease
Cardiovasc Res, February 15, 2006; 69(3): 559 - 561.
[Full Text] [PDF]


Disclaimer:
Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.